Author:
Pfister David,Schmelz Hans U.,Heidenreich Axel
Publisher
Springer Berlin Heidelberg
Reference44 articles.
1. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP (2013) European Association of Urology. EAU guidelines on testicular cancer: 2011 update. Eur Urol 60(2):304–319
2. Bachner M, Loriot Y, Gross-Goupil M et al (2012) 2-18fluoro-deoxy-d-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 23:59–64
3. Besse B, Grunenwald D, Fléchon A et al (2009) Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thorac Cardiovasc Surg 137(2):448–452
4. Beyer J, Albers P, Altena R, et al (2012) Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol [Epub vor Druck]
5. De Santis M, Becherer A, Bokemeyer C et al (2004) 2-18fluoro-deoxy-d-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 22:1034–1039